TABLE OF CONTENTS

Message from the President

Highlights of 2017
- ECL Executive Board
- General Assembly and Conference
- Patient Support Working Group
- Access to Medicines Task Force
- MEPs Against Cancer
- Tobacco Control Activities
- European Code Against Cancer

ECL Secretariat Activities

ECL Members

Financial Report

ECL Membership Overview for 2017
The ECL has established its status as one of the major players in cancer-related policies and activities in Europe. ECL enjoys respect from the European Commission, members of the European Parliament and other European organisations and it is a popular partner in international collaborations. The year 2017 was, once again, busy and productive for ECL and its members: it gives me great pleasure to report on our joint achievements.

We have now 26 member leagues in 23 countries. Several national leagues have expressed their interest in ECL and we hope to have even larger membership in future.

In 2017, ECL continued to work on the dissemination of the European Code against Cancer (launched in October 2014) and organised several workshops. One of the major events was organised in Coimbra in November by the Portuguese League Against Cancer. I had a pleasure to speak on behalf of the ECL at that event. The Code is an excellent tool for cancer leagues and governments to enhance health promotion and prevention of non-communicable diseases. ECL does its best to make the Code widely known and used in all European countries. This activity is mainly financed by the Operating Grant of the European Commission. In 2017, the European Commission decided on the new four-year Operating Grant for the ECL. I would also like to thank Garnier for its unrestricted grant to our work to prevent skin cancers.

ECL further strengthened its role as the Secretariat for Members of European Parliament (MEPs) against Cancer (MAC) group in the European Parliament. This group aims to raise awareness of cancer at the political level, focusing on the many dimensions of cancer: prevention and promotion of health, protection of citizens from risks and cancer survivorship, among others. This dynamic group of MEPs are committed to working together, and cooperate with ECL to organise meetings on many aspects of cancer control, from prevention to rehabilitation. We look forward to future collaboration with our supportive Members of European Parliament.

The Task Force for Equal Access to Medicines, originally initiated by the Dutch Cancer Society continued its systematic work to increase equity in cancer care. There are still inequities between European countries in access to cancer medication. Furthermore, in many countries there are major delays before cancer patients get the best available treatment.

The Patient Support Working Group (PSWG) is in the core of the ECL’s mission. All cancer leagues aim to guarantee best possible care and support for cancer patients. PSWG is a forum for sharing best practices and creating new joint initiatives.

I would like to thank all working group and task force chairs and members of their convincing work with impact in 2017.

In September 2017, the Danish Cancer Society hosted the ECL meetings and Annual Conference in Copenhagen. These events were perfectly organised, the programme been ready almost a year ahead. We could enjoy top class key note lectures, inspiring meetings and a splendid social programme.

I would like to extend my warmest thanks to our member leagues, the very committed and encouraging Board Members and to the always trustworthy and competent Secretariat. Our impact on cancer control in Europe and our good reputation are very much based on the strong national influence of the leagues, the excellent work our staff is doing and the Board Members representing ECL in various important events.

Sakari Karjalainen
ECL President
HIGHLIGHTS OF 2017

ECL Executive Board

The 2017 Executive Board comprised of the following members:

Sakari Karjalainen, President, Cancer Society of Finland
Rui Medeiros, Vice President, Portuguese League against Cancer
Roisin Foster, Treasurer, Cancer Focus Northern Ireland
Jacqueline Godet, French Cancer League
Elizabeth Horth, Danish Cancer Society
Nicolas Philippou, Cyprus Association of Cancer Patients and Friends

ECL Board Activities Report

Following the statutes and by-laws stipulating that the Board should meet at least four times a year, since the last General Assembly, the ECL Executive Board will have met 4 times by the time of the General Assembly in Copenhagen. The Board had a teleconference on 8 December 2016, which replaced a physical meeting originally planned in Copenhagen on 28 November and cancelled. The Board had another teleconference on 31 March 2017, and a physical meeting in Copenhagen on 20 June. The Board will meet, as per every year, before the ECL Annual Conference and General Assembly on 27 September at the Danish Cancer Society.

In addition to the meetings and teleconference, there are regular email correspondences and meetings at cancer conferences and events between the Board members, especially the President, Vice-President and Treasurer, and the Secretariat. On 3 May, the President and Treasurer met with the Secretariat while they were in Brussels for the Policy Officer interviews.

Notable agenda items for Board meetings this year included the monitoring of activities being implemented and deliverables of the EU Operating Grant, especially in relation to the dissemination of the European Code Against Cancer; recruiting a new Policy Officer for the Secretariat; reviewing the process of organising the European Conferences on Tobacco or Health (ECToH), for which ECL has permanent responsibility; the need for a website revamp and new webmaster in view of the increasing problems ECL was facing with its website and rejected emails; and the organisation of the annual meetings and side events in Copenhagen.

Overall, the Board is responsible for ECL’s strategy, directions and main activities, including the renewal of ECL’s Strategy 2014-2018, organisational development, communications and relationship with members and other relevant organisations.
As President, Sakari Karjalainen was in regular contact with the Secretariat staff in Brussels, in particular with the Director who reports directly to him. As President of the Board, he oversees the activities of the office in Brussels and chairs all Board meetings and teleconferences. Sakari is the official ECL representative in the European CanCer Organisation (ECCO) where ECL is a member as of 2016 after ECCO’s restructuring. Sakari speaks on behalf of the ECL at external meetings, such as those at the European Parliament, and provides advice to the ECL Secretariat on a regular basis. As the Work Package leader for the Joint Action on Cancer Control (Cancon) 2014-2017 which ended in February, Sakari has involved ECL as its Associated Partner in dissemination activities. Along with Elizabeth Hjorth, he is our Board contact for the Nordic Cancer Union (NCU) and informs at every Board meeting relevant news from the NCU and vice versa, acting as an important link with the Nordic countries. Sakari was among the impressive list of high-level speakers at the World Cancer Leaders' summit at the World Cancer Congress in October 2016, hosted by the French League, where he spoke on "Civil Society as a Catalyst". In May, Sakari assisted in the interviewing and selection of a new Project and Policy Officer. As the Cancer Society of Finland will be leading on the Work Package on prevention and screening in the next cancer control Joint Action iPAAC, Sakari will again ensure that ECL will have an important role working alongside the Member States.

Vitor Veloso, President of the Portuguese League, as Vice-President until September 2017, assists the President in her management tasks, including maintaining regular contacts with the Brussels office. He is the board contact for the Mediterranean area and keeps the Secretariat and ECL members updated with relevant news from the region. He is also the Board contact for cancer and primary prevention advice as his league is very active in this area, and has been instrumental in providing best practice case studies for previous conferences for the European Week Against Cancer, sun safety meetings, as well as other ECL meetings. He was the Chairman of the Executive Committee of 7th ECToH 2017 which was an undisputed success and gave prestige to the ECL and all the associated Leagues. He also began conversations with the Honorary Chairman of the Associacion Española Contra el Cancer (AECC) HRH Rainha Letizia of Spain and with the Chief Executive Officer in order to strengthen relations but also to encourage them to join the ECL.

Rui Medeiros, as Vice-President since September 2017, works closely with the President. He is the Board contact for primary prevention advice, as his league is very active in this area. His league continues to be vital in providing advice and resources to ECL’s work for the European Code Against Cancer, as the Portuguese League has various campaigns. Prof. Medeiros is the Director of the Research Department-Portuguese League Against Cancer (NRNorth) and the Coordinator of the Molecular Oncology and Viral Pathology Group at the Instituto Portugues de Oncologia do Porto. He has published more than 250 papers in international peer-review journals, and performed hundreds of successful interventions in conferences and scientific meetings. During his career, Prof Rui Medeiros has been awarded with several prestigious national and International Awards and Honours and is part of several national and international associations.

Rosin Foster is the ECL Treasurer and therefore responsible for the finances of the Association, working closely with the ECL Accountant and Auditor. She monitors the financial situation of ECL and discusses financial and administrative issues with the other Board members and the Secretariat. She provides advice to the Secretariat when required regarding the relationship with the Auditor and Treasurer. She will also work closely with the ECL Financial Officer when a new one is in place. Rosin is also our Board contact for the Patient Support Working Group, where one of her staff members is chair. Rosin was in the Board subgroup meeting to review the ECL by-laws as well as terms and conditions of employment for the ECL staff. Rosin was on the selection committee for ECL’s new Project and Policy Officer in May.
**Elizabeth Hjorth** is the legal counsel for the Board and ECL. She has been responsible for reviewing the ECL By-Laws and making suggestions for future amendments. She also helped review terms of a possible collaboration with an external organisation (European Cancer Concord). Elizabeth has been hosting Board meetings at the Danish Cancer Society this past year, in particular to discuss the organisation of the 2017 annual meetings which are also being hosted by the Danish Cancer Society. Elizabeth has been instrumental in connecting relevant colleagues in specific areas of work with ECL, such as in prevention related to the European Code Against Cancer and the Access to Medicines Task Force. Along with Sakari, she is the Board contact for the Nordic Cancer Union and is an important link with the Nordic countries.

**Jacqueline Godet** is instrumental in ensuring that the Access to Medicines Task Force has been supported by her team, as one of the leagues who helped develop the Task Force with the Dutch Cancer Society. Jacqueline involves ECL in the French League’s International Inter-Commission Committee (ICI) to allow ECL’s input into the French League’s international affairs, which includes a wide range of issues including tobacco control and access to medicines. She has helped give visibility to the ECL Youth Ambassadors’ (YA) Group by inviting one of the YAs to be part of the ICI. This year, she has been extremely busy in her own country as they celebrated La Ligue’s 100 years, with a large event on cancer prevention at the end of the year.

**Nicolas Philippou** is the Board contact for the Access to Medicines Task Force and provides guidance on issues of Patient Support. Nicolas has a formal education in business management and currently acts as a CEO of the Cyprus Association of Cancer Patients and Friends (PASYKAF). Outside of ECL, Nicolas is an alumni of the European Patients’ Academy (EUPATI), a member of the Patient Advocacy Working Group at the European Society for Medical Oncology (ESMO), and a member of the audit committee at the European Cancer Patient Coalition (ECPC). Given his experience and large network among patient advocates, Nicolas ensures the patient voice is present in all activities ECL undertakes. Moreover, thanks to his background, Nicolas provides financial insight and supports the Treasurer, particularly when Belgian-specific information is sought. Since his election to the ECL Board in September 2017, Nicolas supported the ECL President in attending the German Cancer Society’s European Round Table Meeting on Quality of Cancer Care and represented the Board at the Let’s Talk Access White Paper launch meeting at the European Parliament. Nicolas regularly provides feedback and valuable advice to the work of the ECL Access to Medicines Task Force.

Board members are volunteers. ECL is grateful for their dedication and active contributions to the work of ECL throughout the year, as well as for their timely advice in guiding the ECL Secretariat in its activities.
ECL Annual Meetings, Copenhagen, Denmark, September 2017

Annual Conference, Copenhagen, 28 September 2017
Is Cancer in Control?

WELCOME
- Dorthe Gylling Cruüger, Chairman, Danish Cancer Society
- Sakari Karjalainen, President, Association of European Cancer Leagues
- Christel Schaldemose, MEP

TRANSFORMATION OF EUROPEAN CODE AGAINST CANCER
Cancer prevention Europe – a new initiative in Prevention and communication
- Chris P. Wild, Director, International Agency for Research on Cancer (IARC)
From research hypothesis to public health changes: the whole grain story
- Anne Tjønneland, Head of Research, MD, PhD, DMSc, Danish Cancer Society
HPV- vaccines – results and challenges
- Mette Lolk Hanak, Head of Prevention, Danish Cancer Society

TREATMENT
Equal access to medicines & ECL Task Force
- Michel Rudolphie, CEO, Dutch Cancer Society
Public Priority of Cancer Medicines in Denmark
- Dorthe Crüger, Chairman of the Danish Cancer Society, CEO Hospital Lillebælt, MD PhD.

DIVESTING IN TOBACCO INDUSTRY
What could bring an oncologist to the table in the boardrooms of some of the world’s largest and most influential pension funds/finance companies?
- Bronwyn King, Founder and CEO, Tobacco Free Portfolios

PATIENT SUPPORT
Resilience and Cancer
- Head of Cancer Counselling Centre, MS (psych) Peter Center
Collective Impact - a new approach to solve complex problems
- Ass. Director Elsebeth Kirk Muff, Social Development Centre SUS

CLOSING
- Sakari Karjalainen, President, Association of European Cancer Leagues
The ECL annual meetings in Copenhagen were a great success with many interesting sessions and opportunities for networking.

ECL is grateful to the Danish Cancer Society for having hosted the events in Denmark and for taking very good care of the participants!
Since 2007 the ECL Patient Support Working Group (PSWG) connects cancer care experts who work together on topics such as access to insurance and financial services, return to work, caregiver support, cancer rehabilitation and palliative care. PSWG members share best practices, develop guidelines and other information sources to raise awareness and improve quality of care, and seek to empower the patient voice in national and European policy-making.

PSWG Meetings 2017
Budapest, Hungary, March 2017
Copenhagen, Denmark, September 2017

2017 Work Themes

Published material (available on ECL website)
Guidelines on support for informal caregivers
Guidelines on collaboration with pharmaceutical industry reviewed and published

Work in development
Presentation for employers on return to work after cancer
Survey on sexuality issues
Survey on access to insurance and other financial services in Europe

Best practice sharing
Use of social media in patient support
Supportive and Palliative Care
Established in 2016, the ECL Access to Medicines Task Force (A2M TF) aims to make cancer medicines available for all cancer patients in Europe by insisting on accessibility, sustainability of the healthcare system and transparency of drug prices. The Task Force strongly believes in the power of dialogue. We urge all stakeholders to push for innovative improved treatments, improving both survival and the quality of life of cancer patients, instead of investments in me-too products. Currently, 25 national/regional cancer leagues, representing over 444 million Europeans, have signed the Task Force’s Declaration of Intent.

A2M TF Meetings 2017
Amsterdam, the Netherlands, February 2017
Copenhagen, Denmark, September 2018

Advocacy activities 2017
- Amendments to European Parliament’s report on improving access to medicines, January 2017
- Letter to Commissioner Vestager on the role of EU competition policy in equal access to Medicines, February 2017
- Drafting of White Paper on challenges in access to innovative medicines (to be published in 2018)
- Access to Innovative Oncology Drugs in Europe, CDDF meeting in Madrid, September 2017 (Eveline Scheres as a speaker)
- Event on Legal, Systemic and International Perspectives on Access to Medicines, September 2017 (Copenhagen)
- Press release reaction on BMJ study on cancer drug efficacy, October 2017
- Letter to Health Ministers and Health Attachés on pricing transparency and inter-governmental knowledge sharing, December 2017
- Webinar on CAR T-cell therapies - scientific, legal and political review, December 2017
MEPs Against Cancer (MAC) Parliamentary Interest Group

The MAC Group was founded in 2005 and remains the only dedicated group to cancer policy at the European Parliament. Currently there are 38 MAC members coming from all political groups and different EU Member States. The President Mr. Alojz Peterle (EPP, Slovenia), Vice-Presidents Ms. Nessa Childers (S&D, Ireland), Mr. Pavel Poc (S&D, Czech Republic), and Dr. Charles Tannock (ECR, United Kingdom), and other members are committed to taking action in the fight against cancer. The MEPs Against Cancer (MAC) work together in order to improve cancer control and prevention in Europe, in the belief that European cooperation adds value to member state actions. In order to address the challenges faced by the EU, MAC collaborate with the European Commission, the Council and other relevant organisations to reduce cancer incidence by 15% by 2020.

ECL provides secretariat and knowledge support to members of the MAC Group.

**Strategic goals 2014-2019:**

1. Reduce cancer incidence by promoting prevention;
2. Reducing mortality by ensuring equitable access to high quality treatment and care
3. Ensure a good quality of life for cancer patients and survivors.

**Meetings/Activities 2017**

- World Cancer Day - MEPs Joint Statement, February 2017
- Alternative Diagnostic Methods, February 2017 (Brussels)
- Cancer Screening, June 2017 (Brussels)
- Sunbeds use: all cost, no benefit, June 2017 (Brussels)
- Occupational Cancer in Firefighters, September 2017 (Brussels)
- Alcohol & Cancer, November 2017 (Brussels)
Traceability standards for tobacco products

Countries and regions are preparing rules for a tracking and tracing regime. In the EU, a tracking and tracing regime for cigarettes will come into force from 20 May 2019. An agreement on those rules is expected by the end of 2017.

Big tobacco is lobbying to have an industry operated system. All major international cigarette companies support the tracking and tracing system, Codentify or Inexto, which they offer at low cost to governments.

In the industry operated option, the manufacturers are responsible for the generation of the unique identifiers which they produce at the manufacturing site outside the control of governments. In addition, in the case of the codentify, the system is not secured as the codes are visible and easy to copy or to clone. Unique identifiers are an important and essential element of any tracking and tracing system. Unique identification markings are an obligation under article 8§3 of the ITP and shall not be performed by or delegated to the industry according to article 8§12.

A tobacco industry operated system would not be an option and against the obligations of the ITP. The Protocol clearly defines that the obligations of the tracking and tracing system shall not be delegated to the tobacco industry. For instance, it is stipulated in article 8 §2 that the tracking and tracing system is “controlled by the Party”. In addition, it was emphasized in article 8 §13 that “each Party shall ensure that its competent authorities, in participating in the tracking and tracing regime, interact with the tobacco industry and those representing the interests of the tobacco industry only to the extent strictly necessary in the implementation of this Article.”

At the 7th Conference of the Parties to the WHO FCTC in India on the 12th November 2016, all Parties to the FCTC agreed and were reminded that “Except interactions to the extent strictly necessary, parties to the Convention are urged not to consider any proposal or assistance related to tracking and tracing from the tobacco industry or submitted on their behalf, including in the course of the preparatory activities for MOP1 in accordance with their obligation under WHO FCTC.”

The Sixth Tobacco control scale

The new Tobacco Control Scale was launched at the 7th European Conference on Tobacco or Health (ECToH) showed United Kingdom as a fourth time winner while three countries, Austria, Germany and Luxembourg continue to disappoint with extremely poor scores.

The new ranking report described the results of a survey of tobacco control activity in 35 European countries in 2016. The tobacco control scale quantifies the implementation of tobacco control policies at country level, and is based on six policies described by the World Bank, which they say should be prioritised in a comprehensive tobacco control programme.
The Russian Federation was included in our survey for the first time and was doing well in advertising restrictions and smoke free policies, but the score attributed to prices was low. Romania made spectacular progress jumping to 7th place from 19th in 2013.

Overall, countries which failed to undertake new initiatives lost points and fell in the ranking. The countries that are leading tobacco control in Europe are those that have comprehensive tobacco control policies. Six countries (UK, France, Ireland, Hungary, Norway and Slovenia) adopted plain packaging legislation, although only the UK and France had plain packs at the point of sales on 1 January 2017. Since 2013, nine countries have introduced a smoking ban in private cars when minors are present. (Ireland, UK, France, Finland, Italy, Malta, Cyprus, Lithuania and Slovenia).

Meetings and speaker at conferences

- Attendance of the WHO FCTC Conference of Parties meeting in Delhi in November 2016
- EU Commission expert on traceability of tobacco products in December 2016
- Meeting on 16 January 2017 on the impact assessment of the tobacco tax Directive
- Speaker at the Tax Stamp forum in Berlin in January 2017
- Working meeting on the new website of the Tobacco Control Scale in Barcelona in February 2017
- Speaker at the hearing in Belgian Parliament on tobacco control in March 2016
- Sixth Tobacco Control Scale at ECTOH in March 2017 in Porto
- Attendance at the stakeholders meeting of the Commission on traceability in May 2017
- Launch of the book on the tobacco lobby in Belgium on 18 May 2017
- EU Advocacy Summit organised by Pfizer in Madrid in June 2017
- Speaker at a Hearing organized by the German Federal Ministry on traceability standards in July 2017 in Berlin

Perspectives 2017-2018

- Further development of the Tobacco Control Scale: website, research on the effect of the TCS and preparation of the next edition
- Review of the EU Tobacco Tax Directive
- Elaboration of EU standards for the traceability of tobacco products
- Attendance at the Seventh Conference of the Parties of the WHO FCTC in Geneva in October 2018 and eventually the First Meeting of the Parties of the Illicit Trade Protocol, if 40 parties have ratified the ITP before 2th July 2018.
European Code Against Cancer

Introduction
The European Code Against Cancer (ECAC) is an initiative of the European Commission, developed by the World Health Organization’s International Agency for Research on Cancer (IARC). The ECAC aims to inform people about actions they can take for themselves or their families to reduce their risk of cancer. Leading cancer scientists from across Europe compiled the ECAC based on the latest scientific evidence on cancer prevention, coming up with twelve recommendations that most people can follow without any special skills or advice. It has been estimated that almost half of all deaths due to cancer in Europe could be avoided if everyone followed the recommendations.

1. Do not smoke
   Do not use any form of tobacco.

2. Make your home smoke free
   Support smoke-free policies in your workplace.

3. Take action to be a healthy body weight
   Limit the time you spend sitting.

4. Be physically active in everyday life
   Eat plenty of whole grains, pulses, vegetables and fruits.
   Limit high-calorie foods (foods high in sugar or fat) and avoid sugary drinks.
   Avoid processed meat, limit red meat and foods high in salt.

5. Have a healthy diet:
   Breastfeeding reduces the mother’s cancer risk. If you can, breastfeed your baby.
   Hormone replacement therapy (HRT) increases the risk of certain cancers. Limit use of HRT.

6. If you drink alcohol of any type, limit your intake
   Not drinking alcohol is better for cancer prevention.

7. Avoid too much sun, especially for children
   Use sun protection. Do not use sunbeds.

8. In the workplace, protect yourself against cancer-causing substances by following health and safety instructions

9. Find out if you are exposed to radiation from naturally high radon levels in your home
   Take action to reduce high radon levels.

10. For women:

11. Ensure your children take part in vaccination programmes for:
   - Hepatitis B (for newborns).
   - Human papillomavirus (HPV) (for girls).

12. Take part in organized cancer screening programmes for:
   - Bowel cancer (men and women).
   - Breast cancer (women).
   - Cervical cancer (women).

The European Code Against Cancer focuses on actions that individual citizens can take to help prevent cancer.

Find out more about the European Code Against Cancer at: www.cancercode.eu

These recommendations are the result of a project coordinated by the International Agency for Research on Cancer and co-financed by the European Commission.
2017 for Cancer Prevention

EVALUATION OF THE EUROPEAN CODE AGAINST CANCER (ECAC)

A follow-up survey on the public awareness of the ECAC was performed in November 2017 demonstrating an overall increase in the awareness of the ECAC in the surveyed countries (13% of respondents had previously heard about ECAC). The survey was conducted in 8 countries (Finland, France, Hungary, Poland, Portugal, Rep. of Ireland, Spain, UK) with over 8,000 participants. 18% of respondents aged 18-24-year olds had previously heard of the ECAC, which is encouraging given the emphasis on promoting ECAC to young people.

SCREENING

Cancer Screening in the EU (hosted by MEPs Deirdre Clune and Pavel Poc, organised by ECL), 1 June 2017, Brussels, 32 participants from 13 countries. The meeting was held at the close of the European Week against Cancer on 1 June 2017. The report was drafted and published online before the end of the month, in line with the publication target. 30 people registered to event and of the those participating, 87% rated the workshop highly useful for their daily practice.

MICROGRANTS

Local dissemination projects were conducted by 5 cancer leagues: FECEC (Catalonia), Romanian Cancer Society, Hungarian League against Cancer, Portuguese League against Cancer, and Polish League against Cancer. The projects included a national roadshow in Hungary to promote cancer prevention, a series of scientific talks aimed at the general population in Portugal, and support for the annual Catalan Cancer Prevention week, which focused on messages 4 & 5 of the ECAC (physical activity and nutrition).

TOBACCO CONTROL SCALE MAP

An interactive atlas of the tobacco control scale was produced which is a pilot version of a concept that will be extended to all 12 messages of the ECAC.

ECL YOUTH AMBASSADORS FOR THE ECAC

The ECL Youth Ambassadors convened their third annual workshop resulting in July 2017. This led to new modalities such as a Twitter chat concept to promote the messages of the ECAC. The youth ambassadors produced a video to promote the ECAC commemorating the 30th anniversary of the first edition of the ECAC. The video reached over 36,000 people on Facebook and was viewed more than 20,000 times.

Over the year new ambassadors joined the group up to a total of 24 members embracing new commitments.

ECAC TOOLKIT

A communication toolkit was produced as planned and made available on the ECL website for public download. The toolkit synthesises the learning from the action and that of previous year’s and provides essential guidance for communicating ECAC.

EVENTS FOR ECL MEMBERS

Cancon Final Conference, promoting ECAC to decision makers and policymakers
Malta, February 2017

ECToH conference, session on ECAC
Porto, Portugal, March 2017

Site visit, Danish Cancer Society
Copenhagen, Denmark, June 2017

ECL Annual Meeting, side session on cancer prevention
Copenhagen, Denmark, September 2017

Codigo Europeu Contra o Cancro
Coimbra, Portugal, November 2017
ECL SECRETARIAT ACTIVITIES

Secretariat activities are planned and implemented in line with ECL Strategic Goals as part of the ECL Strategy 2014-2017.

Given its distinct importance, details for ECL’s Tobacco Control activities are provided separately.

ECL’s activities and resources increased during 2015-2017 due to the successful application for EU co-funding in the form of an Operating Grant. This year, 2017, is the last of the three years of this Operating Grant period. ECL applied for another Operating Grant in June.

The vision of Association of European Cancer Leagues (ECL) is for a Europe Free of Cancers. The role of ECL is to facilitate the collaboration between cancer leagues throughout Europe and to influence EU and pan-European policies. The mission of the Association of European Cancer Leagues is to influence and improve cancer control and cancer care in Europe through collaboration between its members in their fight against cancer, and to influence EU and pan-European policies.

The ECL Secretariat was staffed by the following in 2017:

A. The core staffing at the ECL Secretariat in Brussels:
   - Wendy Yared, Director at 100%
   - David Ritchie, Senior Cancer Control Officer at 100%
   - Anna Prokupkova, Policy and Project Officer at 100% from 1 June 2017
   - Kate O’Regan, Policy and Project Officer at 100% until 24 March 2017
   - Ghislaine Gerbier, Administrative Coordinator at 50%
   - Martina Chen, Financial Officer at 50% until 13 January 2017
   - Luk Joossens, Tobacco Control Advocacy Officer, at 20%

B. Additionally in 2017
   - Mariami Beridze - March-May 2017
   - Laurianne Péron - August-October 2017
   - Student researchers and interns on as-needed basis for research on obesity and cancer, for commitment in EU Platform on Diet, Physical Activity, and Health.

ECL Secretariat Activities

A. Events and meetings organised by ECL and relevant associations:
   ECL has been active in varying capacities, as (co-) organisers, speakers, or committee member in more than forty meetings.

B. EU institutions
C. Networking with other organisations

ECL meets regularly with various umbrella organisations to exchange information on current activities and future actions, and to strengthen collaboration, notably with IARC (the WHO’s International Agency for Research on Cancer), WHO (World Health Organization), ECCO (European CanCer Organization), ESMO (European Society for Medical Oncology), UEG (United European Gastroenterology), ELPA (European Liver Patients Association), UICC (Union for International Cancer Control), SFP (Smoke Free Partnership, with whom ECL has a Memorandum of Understanding), ENSP (European Network for Smoking Prevention), EPHA (European Public Health Association), EIWH (European Institute on Women’s Health), ECPC (European Cancer Patient Organisation), IDF (International Diabetes Federation), European Association for the Study of Obesity (EASO), European Patient’s Forum (EPF), the Health and Environment Alliance (HEAL), the European Society for Paediatric Oncology (SIOPE), the Cancer Research UK (CRUK), the European Alcohol Policy Alliance (Eurocare), and oth.

Information gathering and distribution

The ECL office is responsible for collecting and disseminating relevant information:

A. General Information Dissemination and ECL newsletters

i. Collect / request / seek information from ECL members, for each issue of the ECL Newsletter.
ii. Collect relevant information by conducting active searches online and contacting our members directly, including in 2017:
   a) Regular events and campaigns led by member leagues;
   b) News from the Joint Action CanCon (Cancer Control);
   c) Regular policy updates from developments in the EU, MEPs Against Cancer and the Alcohol and Health Forum;
iii. Report on the Patient Support Working Group and other themed activities, such as the EU platforms on alcohol and health and on nutrition, physical activity and health; cancer prevention information; Tobacco Control;
iv. Disseminate by email relevant information and meeting / conference invitations which arrive at the ECL office;
v. Disseminate monthly newsletters via email, the ECL website and social media

B. Providing Content and Managing the ECL Website and Social Media Presence

The Secretariat staff is responsible for providing content into the ECL website www.europeancancerleagues.org. The office also maintains Facebook pages and Twitter feed. Facebook pages and Twitter pages exist for ECL (@cancerleagues), MEPs Against Cancer (@MAC_MEPs), the European Week Against Cancer (@EU_EWAC), the European Conference on Tobacco or Health (@ECToH), obesity and cancer (@obesitycancer) and alcohol and cancer (@alcoholcancerEU).

Specific communication strategy for the European Code Against Cancer has been continued in 2017. This encompasses the www.cancercode.eu website domain; @cancercode twitter account; and Facebook pages. ECL Youth Ambassadors are now taking greater responsibility for the promotion of the ECAC on social media.

C. Respond to requests for information
**Capacity Building**

A. **Support to Patient Support Working Group**

The ECL secretariat supports the ECL Patient Support Working Group (PSWG), which is being chaired by the Cancer Focus Northern Ireland.

B. **Support to Access to Medicines Task Force**

The ECL Secretariat supports the ECL Access to Medicines Task Force, which is being chaired by the Dutch Cancer Society.

C. **Support for Themed Activities**

The office assists in consolidating information, working with the relevant Board members, and contacting other organisations related to themed activities, such as for the Joint Action on Cancer Control by supporting the Cancer Society of Finland in disseminating information on the Joint Action, updates on tobacco control issues, such as news on the Tobacco Products Directive (TPD), via the ECL advocacy officer; collaborate with the next host of the European Conference on Tobacco or Health (ECToH) in March 2017 to be hosted by the Portuguese League and Board member Vitor Veloso and follow up actions and events on cancer at the European Parliament.

D. **Organisation of workshops and roundtables 2017**

i. MEPs Against Cancer meetings at the European Parliament (listed above)
ii. Roundtable on Access to Cancer Treatment with the Flemish League
iii. ESMO Rare Cancers Consensus Meetings
iv. ECAC session at ECToH, March (Porto)
v. European Code Against Cancer 5th dissemination workshop, February (Malta)
vi. European Code Against Cancer 6th dissemination workshop, September (Copenhagen)
vii. 3rd annual Youth Ambassadors for Cancer Prevention workshop, July (Brussels)
viii. ECL Annual General Assembly, October (Paris)

E. **General administration of the ECL office**

i. Administration of the office, contracts, finances (bank, accounting and auditing), material and relations with Foundation Against Cancer Belgium, who is hosting the ECL office;
ii. Administration of staff: management of salary payments, of reporting both internal and to the Board, of holidays and travels;
iii. Work with the Accountant, Auditor, and Board Treasurer to monitor and update finances;
iv. Liaising with the Board, in particular with the President, Vice-President, and the Treasurer;
v. Work with the Board in shortlisting and recruiting of new staff;
vi. Monitoring of ECL internal rules and By-Laws;
vii. Development of promotion and marketing material and dissemination of such; and
viii. Regular updates to the ECL Board at Board Meetings of the secretariat’s activities.

F. **Industry Contributions**

Maintain relationship with Garnier International on collaboration of 3-year contracts (last renewed in 2015).

ECL accepts only contributions in the form of unrestricted educational grants, and on the condition that companies cannot influence how the funding is used by ECL.
ECL MEMBERS

BELGIUM
Foundation Against Cancer
Fondation contre le Cancer
Chaussée de Louvain 479, 1030 Brussels
Tel: +32 2 736 99 99
Website: www.cancer.be
E-mail: info@cancer.be

Stand Up to Cancer (Flanders)
Kom Op Tegen Kanker
Tel: +32 2 227 69 69
Koningsstraat 217, 1210 Brussels
Website: www.komoptegenkanker.be
E-mail: info@komoptegenkanker.be

Catalan Federation of Entities against Cancer (FECEC)
Hotel d'Entitats La Pau,
C/Pere Vergés, 1 11a planta
08020 Barcelona
Tel: +34 93 314 87 53
E-mail: gerencia@juntscontraelcancer.cat
Website: www.juntscontraelcancer.cat/en/

DENMARK
Danish Cancer Society
Kræftens Beæmpelse
Strandboulevarden 49, DK-2100 Copenhagen
Tel: +45 35 25 75 00
Website: www.cancer.dk
E-mail: info@cancer.dk, eh@cancer.dk

CZECH REPUBLIC
League Against Cancer Prague
Liga Proti Rakoviné Praha
Na Truhlarce 100/60, CZ-180 81 Prague
Tel: +420 224 919 732
Website: www.lpr.cz
E-mail: lpr@lpr.cz

FAROE ISLANDS
The Faroese Cancer Society
Føroya Felag Móti Krabbameini
Grønlandsvegur 58,P.O. Box 1216,
FO-100 Tórshavn
Tel: +298 317 959
Website: www.krabbamein.fo
E-mail: ffk@post.olivant.fo

CYPRUS
The Cyprus Association of Cancer Patients and Friends
12-14 Photinou Pana Street, 1045 Nicosia
P.O. Box 23868, CY-1687 Nicosia, Cyprus
Tel: +357 22 345 444
Website: www.cancercare.org.cy
E-mail: caocpat@cytanet.com.cy

The Cyprus Anti-Cancer Society
Paraskeva Ioannou 2
CY-2420 Strovolos
Tel: +357 22 497 373
Website: www.anticancersociety.org.cy
E-mail: vassilis.i@anticancersociety.org.cy

FINLAND
Cancer Society of Finland
Unioninkatu 22
00130 Helsinki, Finland
Tel: +358 9 135 3310
Website: www.cancer.fi
E-mail: tiedotus@cancer.fi, Sakari.Karjalainen@cancer.fi

FRANCE
French Cancer League
Ligue contre le Cancer
14, rue Corvisart
75013 Paris
Tel:+33 1 53 55 28 89
www.ligue-cancer.net
SLOVENIA
Association of Slovenian Cancer Societies
Zveza slovenskih društev za boj proti raku
Zaloska Cesta 2, 1001 Ljubljana, Slovenia
Tel: 386 01 4309 780
E-mail: MZakelj@onko-i.si

SWITZERLAND
Swiss Cancer League
Krebsliga Schweiz
Effingerstrasse 40, Postfach 8219,
CH-3001 Berne, Switzerland
Tel: +41 31 389 91 10
Website: www.swisscancer.ch
E-mail: info@liguecancer.ch,
kathrin.kramis@krebsliga.ch

TURKEY
Turkish Association for Cancer Research and Control
Türk Kanser Araştırma Ve Savaş Kurumu
Atac sokak No:21/1, 06410 Yenisehir-Ankara, Turkey
Tel: +90-312-431 2950
Website: www.turkkanser.org.tr
E-mail: info@turkkanser.org.tr,
tkuluk@gmail.com

UNITED KINGDOM
Cancer Focus Northern Ireland
40-42 Eglantine Avenue,
BT9 6DX Belfast, Northern Ireland
Tel: +44 (0)28 9066 3281
Website: www.cancerfocusni.org
E-mail: hello@cancerfocusni.org
## European Cancer Leagues ASBL
Chaussée de Louvain 479
1030 Brussels

### BALANCE SHEET AS OF DECEMBER 31, 2017

#### ASSETS

**FIXED ASSET**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Website</td>
<td>4,198.00</td>
</tr>
<tr>
<td>Depreciation</td>
<td>-1,399.19</td>
</tr>
<tr>
<td>Furniture</td>
<td>5,325.84</td>
</tr>
<tr>
<td>Depreciation</td>
<td>-4,758.05</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>3,385.60</strong></td>
</tr>
</tbody>
</table>

**AMOUNTS RECEIVABLE WITHIN ONE YEAR**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Receivables</td>
<td>0.00</td>
</tr>
<tr>
<td>Other receivables</td>
<td>2.41</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>2.41</strong></td>
</tr>
</tbody>
</table>

**CASH AT BANK AND IN HAND**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>BNP Paribas Fortis Bank</td>
<td>400,768.69</td>
</tr>
<tr>
<td>Business depo</td>
<td>13.34</td>
</tr>
<tr>
<td>Pretty cash</td>
<td>84.39</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>400,866.42</strong></td>
</tr>
</tbody>
</table>

**DEFERRED CHARGES AND ACCRUED INCOME**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prepaid expenses</td>
<td>3,539.94</td>
</tr>
<tr>
<td>Accrued revenues</td>
<td>124,032.96</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>127,589.89</strong></td>
</tr>
</tbody>
</table>

**TOTAL ASSETS**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td><strong>531,804.32</strong></td>
</tr>
</tbody>
</table>

#### LIABILITIES

**SOCIAL FUND OF THE association**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social fund</td>
<td>37,110.00</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>37,110.00</strong></td>
</tr>
</tbody>
</table>

**RESERVES**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Social liability</td>
<td>204,000.00</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>204,000.00</strong></td>
</tr>
</tbody>
</table>

**ACCUMULATED RESULT**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenues in excess of expenses</td>
<td>162,780.92</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>162,780.92</strong></td>
</tr>
</tbody>
</table>

**AMOUNTS PAYABLE WITHIN ONE YEAR**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suppliers and invoices to be received</td>
<td>13,687.01</td>
</tr>
<tr>
<td>Taxes to be paid</td>
<td>15,413.83</td>
</tr>
<tr>
<td>Salaries and social security to be paid</td>
<td>29,537.41</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>58,638.25</strong></td>
</tr>
</tbody>
</table>

**ACCUERED CHARGES AND DEFERRED INCOME**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deferred income</td>
<td>69,275.15</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>69,275.15</strong></td>
</tr>
</tbody>
</table>

**TOTAL LIABILITIES**

<table>
<thead>
<tr>
<th>Description</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td><strong>531,804.32</strong></td>
</tr>
</tbody>
</table>
### P&L ACCOUNT AS OF DECEMBER 31, 2017

#### OPERATING INCOME AND CHARGES

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Turnover: Membership fees</td>
<td>178,536,80</td>
</tr>
<tr>
<td>Sponsoring</td>
<td>47,000,00</td>
</tr>
<tr>
<td>Grant EC</td>
<td>324,128,69</td>
</tr>
<tr>
<td>Other income</td>
<td>71,135,20</td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td><strong>820,800,69</strong></td>
</tr>
<tr>
<td>Services and other goods</td>
<td>-234,892,68</td>
</tr>
<tr>
<td>Remuneration and social security costs</td>
<td>-273,667,76</td>
</tr>
<tr>
<td>Depreciation</td>
<td>-1,965,95</td>
</tr>
<tr>
<td><strong>Operating profit</strong></td>
<td><strong>110,274,30</strong></td>
</tr>
</tbody>
</table>

#### FINANCIAL INCOME AND CHARGES

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Financial income</td>
<td>378,90</td>
</tr>
<tr>
<td>Financial charges</td>
<td>-852,98</td>
</tr>
<tr>
<td><strong>Current profit of the year</strong></td>
<td><strong>109,800,22</strong></td>
</tr>
</tbody>
</table>

#### EXTRAORDINARY INCOMES AND CHARGES

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Extraordinary incomes</td>
<td>0,00</td>
</tr>
<tr>
<td>Extraordinary charges</td>
<td>-33,990,84</td>
</tr>
<tr>
<td>Withholding tax on financial income</td>
<td>0,00</td>
</tr>
</tbody>
</table>

#### REVENUES IN EXCESS OF EXPENSES

<table>
<thead>
<tr>
<th>Item</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>75,809,38</strong></td>
</tr>
</tbody>
</table>
AUDITOR’S REPORT FOR THE FINANCIAL YEAR STARTED ON THE
1ST JANUARY 2017 AND ENDED ON THE 31ST DECEMBER 2017 OF THE ASSOCIATION
OF EUROPEAN CANCER LEAGUES (ECL) (RPR 0867.170.595)

Objective and scope of the review

Upon the request of the Director, we have reviewed the accompanying financial statements of
the ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL) as at December 31st, 2017.
The Board of Directors of ECL is responsible for the preparation of this financial information in
accordance with the Belgian generally accepted accounting principles. These statements
indicate a balance sheet total of € 531,804,32 as well as revenues in excess of expenses of
€ 75,809,38.

We conducted our review in accordance with the legal requirements and the Auditing
Standards applicable in Belgium, as issued by the Institute of Registered Auditors (Institut des
Réviseurs d’Entreprises / Instituut van de Bedrijfsexisoren) and, more particularly, in
accordance with its Standards in regards to a limited review.

This review, in accordance with the aforementioned standards, consists principally of applying
analytical procedures to financial data and making inquiries of persons responsible for
financial and accounting matters.

A limited review is substantially less in scope than an audit, the objective of which is the
expression of an opinion regarding the financial statements. Accordingly, we do not express
an audit opinion. A limited review does not provide assurance that we would become aware of
any or all significant matters that might be identified in an audit.

Review

We have obtained from the management and responsible officers of the Association all of the
explanations and information necessary for our review. We believe that the evidence we have
obtained in our review is sufficient and appropriate to provide a basis for our conclusion.

In our opinion, the financial statements as of December 31st, 2017, were established in
accordance with the financial reporting framework applicable in Belgium and the accounting
records were maintained with the legal and regulatory requirements applicable in Belgium.
The current revenues amount to € 621,179,59 and the expenses amount to € 545,370,21 and hence, the financial statement as at 31st December 2017 indicates revenues in excess of expenses of € 75,809,38.

After thorough examination and analysis of the available documents and data, we can confirm that operating costs were sufficiently justified by supporting documents.

Additional information

The compliance by the Association with the law of 27 June 1921 related to not-for-profit associations, international not-for-profit associations and Associations is the responsibility of management.

Without prejudice to formal aspects of minor importance, the accounting records were maintained in accordance with the legal and regulatory requirements applicable in Belgium.

There are no transactions undertaken or decisions taken in violation of the Associations by-laws or the law of 27 June 1921 related to not-for-profit associations, international not-for-profit associations and Associations that we have to report to you.

Conclusion

We have reviewed the accompanying financial statements of the ASSOCIATION OF EUROPEAN CANCER LEAGUES (ECL) as at 31st of December 2017, prepared by its Board of Directors, indicating a balance sheet total of € 531,804,32 and revenues in excess of expenses of € 75,809,38.

Based on our reviews, nothing has come to our attention that causes us to believe that the financial statements are not prepared, in all material respect, in accordance with the Belgian generally accepted accounting principles.

Zellik, 5th April 2018

Luteijn, Serghini & Co Registered Auditors BV BVBA represented by Saskia Luteijn
MEMBERSHIP OVERVIEW FOR 2018